News|Videos|February 25, 2025

IDSA Makes Statement on HHS Changes to Vaccine Policy, Postponement of Vaccine Meeting

Tina Tan, MD, FIDSA, FPIDS, FAAP, Infectious Diseases Society of America (IDSA) president discusses the changes and offers a glimpse of what the US can expect in terms of limited access to new vaccines, increased incidence rates of disease, and new public health policy regarding immunizations.

The Department of Health and Human Services (HHS) oversees the Centers for Disease Control and Prevention (CDC). And since Robert Kennedy Jr has taken over as HHS Secretary, he has instructed the CDC to no longer publish a public awareness campaign about influenza vaccines,1 and also postponed the CDC’s Advisory Committee on Immunization Practices (ACIP) meeting that was supposed to happen this week. This meeting happens 3 times a year and it is a significant meeting where independent medical advisors discuss scientific data around vaccines. No date has been provided for a rescheduled meeting.

“Vaccines are one of the greatest developments that we've ever had, and it really is a major tool in our ability to control very serious vaccine preventable diseases,” said Tina Tan, MD, IDSA president and professor of Pediatrics, Feinberg School of Medicine, Northwestern University. “So with the removal of public health vaccine information, as well as with the postponement of the ACIP meeting…it will drive the American public to anti-vaccine sites to get their information, and that is a major, major problem.”

Last week, Tan made an official IDSA statement that discussed these ongoing policy changes. In her statement, she wrote, “Weakening our nation’s vaccine infrastructure will lead to significantly lower immunization rates and result in many more outbreaks of serious, preventable hospitalizations and deaths.”

To read the statement, go here.

Although the dismissal of the flu vaccination public awareness campaign being halted is disturbing, the postponing of the ACIP meeting without a future date planned can effectively prevent future vaccines from being utilized.

“If the committee is not able to meet and discuss the evidence for the use of these vaccines, then these vaccines cannot be recommended and cannot be used…the FDA can approve a vaccine, but they don't make the recommendations for the use of the vaccines to the American public. It really is the CDC ACIP that comes out with those recommendations, and all this is based on very scientifically sound data,” Tan said.

References
1. Stone W. Trump administration yanks CDC flu vaccine campaign. NPR. February 20,2025. Accesed February 25, 2025.
https://www.npr.org/sections/shots-health-news/2025/02/19/nx-s1-5302906/cdc-flu-vaccine-campaign-terminated


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.